This article highlights groundbreaking advancements in Canadian dermatology for 2024, emphasizing the approval of versatile therapies like ruxolitinib for vitiligo and mild AD, and roflumilast foam for seborrheic dermatitis and scalp psoriasis. It also explores new treatment options for severe alopecia and acne, marking a pivotal year in dermatological care.
Click here to read the full article.
